Menopause Bill SHOWDOWN: Newsom vs. Halle Berry

Menopause Bill SHOWDOWN: Newsom vs. Halle Berry

Gavin Newsom’s 2028 Run Jeopardized by Celebrity CLASHHalle Berry just turned Gavin Newsom’s menopause-bill veto into a blunt warning: if he wants the White House, he can’t keep brushing off issues that hit millions of American women.

Story Snapshot

Halle Berry criticized California Gov. Gavin Newsom after he vetoed AB 432, the Menopause Care Equity Act, for a second year.
Berry made the remarks at the New York Times DealBook Summit on Dec. 4, 2025, tying the veto directly to Newsom’s presidential ambitions.
Newsom’s office said the veto was driven by concerns the bill would increase costs, and the governor later said some menopause provisions were placed in the state budget.
The dispute highlights a familiar left-wing governing pattern in California: big promises and slogans collide with taxpayer costs and bureaucratic reality.

Berry’s criticism puts Newsom’s ambitions under a spotlight

Halle Berry used a national stage at the New York Times DealBook Summit in New York City to call out Gov. Gavin Newsom for vetoing AB 432, a bill aimed at expanding insurance coverage for menopause care and encouraging doctor education. Berry argued the repeated veto “overlooked women” and “devalu[ed]” them in midlife. She also suggested the decision should matter politically, saying he “probably should not be our next president either.”

Newsom has been floated as a future national contender, and reporting noted he has discussed the possibility of a 2028 run after the 2026 midterms. Berry’s comment mattered because it didn’t stay in the policy lane—it went straight at electability. For voters tired of celebrity activism, the exchange is still instructive: even in deep-blue California, Democrats face internal pressure when cultural messaging collides with real governance and budgets.

https://x.com/bennyjohnson/status/2015091540016734214?s=20

What AB 432 would have changed—and why Newsom vetoed it twice

AB 432, also described as the Menopause Care Equity Act, sought to mandate insurance coverage for certain menopause treatments and create incentives tied to continuing medical education so doctors receive more training on perimenopause and menopause care. Newsom vetoed the bill in 2024 and again in October 2025. According to his office, the veto rationale centered on costs—warning that new coverage mandates could raise expenses, including premiums, for working families.

This is where the policy dispute gets real, especially for conservative readers who have watched years of “do something” politics turn into bigger bills for ordinary people. The sources do not provide specific fiscal estimates for AB 432, so it’s impossible to independently quantify the premium impact from the available reporting. Still, the stated justification reflects a standard governing tradeoff: mandates can expand access, but they also tend to grow the cost and reach of the system.

Newsom’s response: budget provisions and a push for “collaboration”

After Berry’s criticism went public, Newsom’s team emphasized admiration for her advocacy while defending the veto. A spokesperson said the administration was confident that by working together, access could be expanded in 2026 without driving up costs. Newsom also told TMZ his office was “reconciling this” with Berry’s manager and suggested she did not realize menopause-related provisions had been included in the state budget.

The reporting leaves key details unclear: it does not specify exactly which menopause provisions were added to the budget, how extensive they are, or whether they match what AB 432 would have required from insurers. Without those details, voters are left with a familiar California-style ambiguity—big talk, vague implementation, and a reliance on backroom negotiations after a high-profile veto. That uncertainty matters if Newsom tries to present the episode as “fixed.”

The bigger lesson: coverage mandates vs. affordability in a post-inflation era

Berry pointed to Illinois as a model after it mandated hormone replacement therapy coverage, framing state action as achievable. California’s debate, however, shows why mandates are contentious: they can function like hidden taxes when insurers spread new requirements across premium payers. For conservatives who prioritize limited government and transparency, this is exactly why lawmakers should prove need, show cost, and explain tradeoffs instead of treating every health issue as a blank-check mandate.

Politically, Berry’s criticism also underscores a broader trend inside the Left: celebrity advocates and activists often demand expansive benefits while elected leaders quietly worry about the price tag. Newsom is trying to thread that needle—keeping progressive credibility while avoiding another headline about affordability. Whether he succeeds will depend on what the budget provisions actually do, whether costs rise, and whether women see real improvements in access without another round of bureaucratic runarounds.